Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Plexpress and Admescope Expand TRACPACK ADME-Tox Screening Services

Published: Monday, November 05, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Efficient, accurate drug discovery that works alongside FDA recommendations.

Plexpress, developer of the innovative TRAC platform for high-throughput gene expression analysis, has announced plans to extend its collaboration with the contract research organization (CRO), Admescope. The new TRACPACK INDUCTION Screening Service is optimized for screening high priority drug candidates, producing all the data required to meet FDA regulations. This involves using hepatocytes from three separate donors and generating both CYP mRNA expression and protein activity measurements. For the earlier screening of interesting compounds, the TRACPACK CYP+ mRNA Screening Service is a predictive tool that allows compounds to ‘fail early’ before significant time and resources have been utilized. To facilitate rapid and cost-effective screening this is targeted towards mRNA expression analysis only, analyzing key marker genes for drug transport, toxicity and phase II drug metabolism.

Dr. Jari Rautio, CEO of Plexpress, said: “TRAC is proving highly attractive tool for ADME-Tox related mRNA studies thanks to the numerous cost, time and accuracy benefits it offers when compared to traditional approaches such as qPCR. This interest has also likely been fueled by recent recommendations from the FDA, which suggest that measuring CYP mRNA levels provides the best way to assess drug effectiveness and tolerability (1). Combining high sample throughput with gene multiplexing to increase assay speed while minimizing technical variation, TRAC has the power to significantly boost efficiency in the laboratories of both CROs and Pharma.”

Dr. Ari Tolonen, CEO & CSO of Admescope, commented: “To more effectively meet the needs of our customer’s drug screening programs, we have diversified our ADME-Tox offering to provide both rapid early screening and in-depth analysis.” The TRACPACK-CYP+ mRNA process involves exposing HepaRG cells to a number of test compounds, at different concentrations in technical triplicate, for 24-48 hours. For added reliability, positive control inducers are also included. Following exposure, the cells are lysed in Plexpress’ proprietary TRAC lysis buffer and subjected to gene expression analysis using pre-validated TRAC panels containing up to 30 genes. These include members of the CYP family, providing a reliable indication of drug metabolism, toxicity, transport and efficacy.

TRACPACK INDUCTION expands upon the data offered by the previous service including CYP enzyme activity assays. The enhanced service also increases the number of cell donors to three, maximizing the biological relevance of the results generated and to fulfill FDA requirements. In this way, TRACPACK INDUCTION provides a single, integrated service for all CYP induction analysis, ensuring consistent and reliable data. All TRACPACK results are delivered to the customer electronically, in an easy-to-use, summarized format that makes further data analysis fast and easy.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plexpress Announces ADME-Tox Programs for CRO’s
EMA and FDA recommend mRNA testing in ADME-Tox studies for superior sensitivity.
Friday, May 03, 2013
Plexpress Announces Collaboration with Admescope
CRO to offer TRAC gene expression analysis for pre-clinical ADME-Tox studies.
Thursday, May 17, 2012
Plexpress and SBW Partner to Offer TRAC Gene Expression Analysis
CRO adds TRAC to service portfolio for pre-clinical ADME-Tox studies.
Tuesday, May 08, 2012
Plexpress Secures $2.3M to Commercialize TRAC High-Content Gene Expression Analysis Platform
Company targets applications including companion diagnostics and ADMET.
Thursday, April 19, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos